Nurse Anesthetist - CR in Marinette, WI Accepting Medicare

7 Nurse Anesthetist - CR nurses found. Showing 1 - 7

Brian Ceranski, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 3003 University Dr, Marinette, WI 54143 Phone: 715-735-4200

Willis Fisher, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 617 S Raymond St, Marinette, WI 54143 Phone: 715-732-8855

Michael Swanson, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 3003 University Dr, Marinette, WI 54143 Phone: 715-735-4200

Frank Ziemke, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 3003 University Dr, Marinette, WI 54143 Phone: 715-735-4200    Fax: 715-735-8019

Mr. Robert M Kelly, CRNA Nurse Anesthetist, Certified Registered Medicare: Not Enrolled in Medicare Practice Location: 4061 Old Peshtigo Rd, Marinette, WI 54143 Phone: 715-732-8000    Fax: 715-732-8148

Mr. Robert James Cooper, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 4061 Old Peshtigo Rd, Marinette, WI 54143 Phone: 715-732-8000    Fax: 715-732-8148

Nathan Jay Herrild, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 3003 University Dr, Marinette, WI 54143 Phone: 715-735-4200

News Archive

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

A drug's half-life indicates how long a substance will remain active in the body. It is essentially the period of time that it takes for the concentration of the amount of the drug to be reduced by half, and therefore, determines how frequently a drug needs to be administered to maintain its therapeutic effect.

Study examines incidence of melanoma rates among California Hispanics over time

For the first time, scientists have identified a significant increase in the incidence rate of melanoma-an invasive form of an already deadly skin cancer-among California Hispanics.

Pharming Group NV's pre-BLA meeting with the FDA for Rhucin

Biotech company Pharming Group NV today confirmed its interactions in a pre-BLA meeting with the US Food and Drug Administration (FDA) on a proposed marketing application (BLA or Biologics License Application) to obtain marketing approval for Rhucin for the treatment of acute attacks of HAE (Hereditary Angioedema).

Study shows hormonal therapy increases risk of breast cancer

The study Dr. Chlebowski authored reported that estrogen plus progestin use is linked with increased breast cancer incidence. In addition, it said the prognosis is similar for both users and nonusers of combined hormone therapy, suggesting that mortality from breast cancer may be higher for hormone therapy users as well.

Researchers discover microRNA biomarkers to treat patients with SCLC

Researchers at the Translational Genomics Research Institute, the Van Andel Research Institute and the Virginia G. Piper Cancer Center at Scottsdale Healthcare have discovered a biomarker that could help in the treatment of patients with an aggressive type of lung cancer.

Read more Medical News

› Verified 5 days ago